MetiMedi Co., Ltd.

MetiMedi Co., Ltd. is a bio pharmaceutical company based in South Korea, focused on pioneering research in immuno-oncology. The company is dedicated to developing a groundbreaking oral immunotherapeutic small molecule, METI-101, which is currently in Phase 2 for the treatment of solid cancers. MetiMedi's unique platform technology targets cellular metabolic reprogramming in tumor cells, leading to tumor necroptosis and immune activation while maintaining exceptional safety.

Founded in 2017, MetiMedi is addressing the unmet needs in solid cancer therapies with its innovative approach. Clinical studies have demonstrated the efficacy and safety of METI-101, particularly in refractory metastatic colorectal cancer cases. In addition to its focus on immuno-oncology, MetiMedi operates within the Biotechnology and Health Care industries, positioning itself at the forefront of the healthcare innovation landscape.

MetiMedi's commitment to pioneering cancer therapy, combined with its promising Phase 2 results, presents an opportunity for venture capitalists seeking to invest in cutting-edge bio pharmaceutical solutions. As the company continues to make strides in its clinical development and expand its therapeutic applications, it represents a compelling investment prospect within the rapidly evolving field of immuno-oncology. While the specific details of the last investment and associated investors are currently unavailable, the potential for further growth and impactful advancements in cancer therapy positions MetiMedi as a noteworthy consideration for investment within the healthcare startup ecosystem.